Modality
Degrader
MOA
PARPi
Target
EGFR
Pathway
Angiogenesis
Angelman
Development Pipeline
Preclinical
~Aug 2009
→ ~Nov 2010
Phase 1
~Feb 2011
→ ~May 2012
Phase 2
~Aug 2012
→ ~Nov 2013
Phase 3
~Feb 2014
→ ~May 2015
NDA/BLA
~Aug 2015
→ ~Nov 2016
Approved
Feb 2017
→ Apr 2031
ApprovedCurrent
NCT03419908
1,607 pts·Angelman
2023-11→2031-04·Not yet recruiting
NCT03667932
135 pts·Angelman
2017-02→2026-04·Not yet recruiting
NCT04913753
2,171 pts·Angelman
2021-10→2026-07·Completed
3,913 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2026-04-223w awayPh3 Readout· Angelman
2026-07-174mo awayPh3 Readout· Angelman
2031-04-135.0y awayPh3 Readout· Angelman
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Approved
Not yet…
Approved
Complet…
Approved
Not yet…
Catalysts
Ph3 Readout
2026-04-22 · 3w away
Angelman
Ph3 Readout
2026-07-17 · 4mo away
Angelman
Ph3 Readout
2031-04-13 · 5.0y away
Angelman
CompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03419908 | Approved | Angelman | Not yet recr... | 1607 | ORR |
| NCT03667932 | Approved | Angelman | Not yet recr... | 135 | DOR |
| NCT04913753 | Approved | Angelman | Completed | 2171 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF |